Skip to main content
. 2021 Sep 13;81(21):5572–5581. doi: 10.1158/0008-5472.CAN-20-3242

Figure 1.

Figure 1. We performed RNA-seq on pretreatment biopsies from 43 patients with operable TNBC who received sequential taxane- and anthracycline-based neoadjuvant chemotherapy. At greater than 5-year median follow-up, 14 patients recurred and of those all but two patients had died. At a FDR of 0.05, 33 genes were differentially expressed between patients who did and did not have a subsequent recurrence. IPA demonstrated that one of the top canonical pathways that differed was higher expression of oxidative phosphorylation signature (P < 0.001).

We performed RNA-seq on pretreatment biopsies from 43 patients with operable TNBC who received sequential taxane- and anthracycline-based neoadjuvant chemotherapy. At greater than 5-year median follow-up, 14 patients recurred and of those all but two patients had died. At a FDR of 0.05, 33 genes were differentially expressed between patients who did and did not have a subsequent recurrence. IPA demonstrated that one of the top canonical pathways that differed was higher expression of oxidative phosphorylation signature (P < 0.001).